Search results for: Kenneth Arrow
Filter search results
Consolidation and Competition in the Pharmaceutical Industry
9 January 2001
…becoming a key policy issue alongside the traditional concern with competition between existing products in final markets. Yarrow makes another key point, which is that the need for the additional…
Why Care About Health Inequality?
1 January 2001
…illness; to improve the health of the worst off in society and to narrow the health gap. This monograph looks at health inequalities in the UK from a health economics…
Around The World in HTAs: Spain – Are We There Yet?
15 March 2023
…discussed by the CIPM. Current challenges The standard process to evaluate pharmaceutical products gives a narrow time window of 10 days for REvalMed to conduct the economic evaluation of the…
Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
1 February 2024
…and Opoku, E.E.O., 2023. Environmental degradation and economic growth: Investigating linkages and potential pathways. Energy Economics, 123, p.106734. 10.1016/j.eneco.2023.106734. Arrow, K., Cropper, M., Gollier, C., Groom, B., Heal, G., Newell,…
Employer Costs from Respiratory Infections
16 December 2024
Share this: Download publication Helen Hayes Brittany Darrow Lotte Steuten Graham Cookson Amanda Cole Our latest research shows respiratory infections cost UK businesses £44 billion a year. Workplace vaccination programs…
The UK’s Publicly Funded Vaccines Market
23 November 2010
…data requirements clearer, but adopting the same narrow, NHS-only perspective was considered limiting. Although this may maximise cost-effectiveness, it is not necessarily the most efficient method for the budget of…
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
…footprint compared to shorter- acting alternatives. Realising the potential value of long-acting therapies is currently hindered by a narrow view of value in health technology assessment (HTA) and variability across…
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
…update makes some of the routing criteria more explicit, eligibility continues to apply to only a narrow subset of rare disease treatments. The graph below demonstrates that – for orphan…
An Analysis of NICE’s Optimised Decisions from 2015 to 2024
1 May 2025
Share this: Download publication Brittany Darrow Sulayman Chowdhury Phill O’Neill Nadine Henderson The National Institute for Health and Care Excellence (NICE) is the body responsible for recommending medicines for use…